EurekaMag
+ Translate
+ Most Popular
Gaucher's disease;thirty-two years experience at Siriraj Hospital
A study of Macrobathra Meyrick from China (Lepidoptera, Cosmopterigidae)
First occurrence in ores of tetragonal chalcocite
Effects of trace element nutrition on sleep patterns in adult women
N.Z. range management guidelines. 2. Design of grazing management systems for tussock country
A case of lipoma of the esophagus
A revision of world Acanthosomatidae (Heteroptera: Pentatomidae): keys to and descriptions of subfamilies, tribes and genera, with designation of types
Life history of the coronate scyphozoan Linuche unguiculata (Swartz, 1788)
Perceptual restoration of obliterated sounds
Mutagenicity studies on two chromium(III) coordination compounds
The formation of the skeleton. I. Growth of a long bone. 1st appearance of a center of calcification
Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis
The joint commission: four key root causes loom large in sentinel event data
Treatment of vitiligo with topical 15% lactic acid solution in combination with ultra violet-A
Behaviour of dairy cows within three hours after feed supply: I. Influence of housing type and time elapsing after feed supply
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Management and control of patients with type 2 diabetes mellitus in Lebanon: results from the International Diabetes Management Practices Study (IDMPS)
The diet composition and nutritional knowledge of patients with anorexia nervosa
Physoporella croatica Herak, 1958 of the Slovak karst Anisian (Slovakia, the West Carpathians Mts.)
Bright lights, big noise. How effective are vehicle warning systems?
Ein Plesiosaurier-Rest mit Magensteinen aus mittlerem Lias von Quedlinburg
Incidence of Chlamydia trachomatis in patients with sterility
Monster soup: the microscope and Victorian fantasy
Preliminary tests with residual sprays against poultry lice
Duration of the life of plants in phylogeny

The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development


The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development



Cancer Immunology Research 3(7): 787-794



ISSN/ISBN: 2326-6066

PMID: 25735952

DOI: 10.1158/2326-6066.cir-14-0242

The Epstein-Barr virus (EBV) is an oncogenic, γ-herpesvirus associated with a broad spectrum of disease. Although most immune-competent individuals can effectivley develop efficient adaptive immune responses to EBV, immunocompromised individuals are at serious risk for developing life-threatening diseases, such as Hodgkin lymphoma and posttransplant lymphoproliferative disorder (PTLD). Given the significant morbidity associated with EBV infection in high-risk populations, there is a need to develop vaccine strategies that restore or enhance EBV-specific immune responses. Here, we identify the EBV immediate-early protein BZLF1 as a potential target antigen for vaccine development. Primary tumors from patients with PTLD and a chimeric human-murine model of EBV-driven lymphoproliferative disorder (EBV-LPD) express BZLF1 protein. Pulsing human dendritic cells (DC) with recombinant BZLF1 followed by incubation with autologous mononuclear cells led to expansion of BZLF1-specific CD8(+) T cells in vitro and primed BZLF1-specific T-cell responses in vivo. In addition, vaccination of hu-PBL-SCID mice with BZLF1-transduced DCs induced specific cellular immunity and significantly prolonged survival from fatal EBV-LPD. These findings identify BZLF1 as a candidate target protein in the immunosurveillance of EBV and provide a rationale for considering BZLF1 in vaccine strategies to enhance primary and recall immune responses and potentially prevent EBV-associated diseases.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059005991

Download citation: RISBibTeXText

Related references

Epstein-Barr virus vaccine development: a lytic and latent protein cocktail. Frontiers in Bioscience: a Journal and Virtual Library 13: 5916-5927, 2008

Transcription of the Epstein-Barr virus lytic cycle activator BZLF-1 during oxidative stress induction. Biological Trace Element Research 137(1): 13-22, 2010

Chlorpyrifos Induces the Expression of the Epstein-Barr Virus Lytic Cycle Activator BZLF-1 via Reactive Oxygen Species. Oxidative Medicine and Cellular Longevity 2015: 309125, 2015

Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy. CytoTherapy 16(1): 122-134, 2014

Relationship between the amounts of epstein barr virus dna and epstein barr virus nuclear antigen per cell clonability and tumorigenicity in 2 epstein barr virus negative lymphoma lines and their epstein barr virus converted sublines. International Journal of Cancer 31(2): 163-170, 1983

The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B. Virology 195(2): 578-586, 1993

Rheumatoid arthritis synovial membranes contain a 62 kilodalton protein that shares an antigenic epitope with the epstein barr virus encoded antigen epstein barr virus nuclear antigen. Arthritis and Rheumatism 28(4 Suppl): S41, 1985

Analysis of an ankyrin-like region in Epstein Barr Virus encoded (EBV) BZLF-1 (ZEBRA) protein: implications for interactions with NF-κB and p53. Virology Journal 8: 422, 2011

Establishment of epstein barr virus nuclear antigen expressing cell lines by infection of epstein barr virus genome negative human lymphoma cells with different epstein barr virus strains. International Journal Of Cancer: 161-166, 1976

Transfection of epstein barr virus dna fragments coding for epstein barr virus nuclear antigen 1 and epstein barr virus nuclear antigen 2 into human lymphocytes gene expression without cell immortalization. Journal of Cellular Biochemistry Suppl (10 Part A): 213, 1986

Immune response of mice to a latency membrane protein 2 multiepitope antigen of Epstein-Barr virus applied as DNA vaccine and/or peptide vaccine. Acta Virologica 57(1): 51-58, 2013

Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site. Journal of Virology 74(11): 5151-5160, 2000

Effects of S-adenosylhomocysteine and analogs on Epstein-Barr virus-induced transformation, expression of the Epstein-Barr virus capsid antigen, and methylation of Epstein-Barr virus DNA. Journal of Virology 61(1): 221-224, 1987

The dna binding protein p 53 in epstein barr virus transformed cells properties of this protein other p 53 forms and the epstein barr virus nuclear antigen. Klein, G (Ed ) Advances in Viral Oncology, Vol 2 The Transformation-Associated Cellular P53 Protein Xii+180p Raven Press: New York, N Y , Usa Illus P155-172, 1982

A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 74(9): 2414-2424, 1994